Clinical Study of Generic and Brand Bupropion in Depression

Completed · Phase 4

Conditions studied: Major Depressive Disorder

In brief

Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.

Key facts

Study ID

NCT02209597

Run by

Washington University School of Medicine

People needed

74

Starts

2014-06-25

Expected to finish

2016-08-14

Last updated by the study team

2020-04-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Each subject must meet all of the following criteria:
• Adult outpatients age 18-75 years
• Currently on once daily bupropion HCl 300mg XL (brand or any generic), for a minimum of 4 months
• Major depressive disorder (MDD), in partial or full remission for at least 4 months, as confirmed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Spontaneous relapse of depression unrelated to medication changes is less likely - about 5% chance per year - after remission has been maintained for at least 4 months.2
• Ability to understand and willingness to comply with study procedures, and to provide written informed consent

You may not qualify if…

• Subjects will not be enrolled if any of the following criteria exist:
• Remission from depression not clearly attributed to bupropion treatment
• Current severe side effects attributable to bupropion
• Poor adherence to bupropion treatment per patient self- report and history of refill persistence
• History of active seizure disorder, or seizure treatment within past year
• History of significant hepatic or renal disease, based on physician assessment
• Currently taking drugs or natural products known to influence cytochrome P450B6 (CYP2B6) activity
• Currently taking drugs for hepatitis C or multiple sclerosis, due to their ability to cause depression
• Dementia or other significant cognitive impairment, per diagnosis or investigative team's assessment
• Lifetime diagnosis of schizophrenia, schizoaffective or schizophreniform dis-order, delusional disorder, or current psychotic symptoms diagnosed by SCID
• Abuse of or dependence on alcohol or other substances within the past 6 months as determined by SCID, and confirmed by study physician interview
• Current suicidal ideation

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.